Shirin Nafisi1, Sabyasachi Roy2, Robert Gish1, Richard Manch1, Anita Kohli1. 1. a Department of Hepatology, Dignity Health , St. Joseph's Hospital , Phoenix , AZ , USA. 2. b Department of Internal Medicine, Dignity Health , St. Joseph's Hospital , Phoenix , AZ , USA.
Abstract
UNLABELLED: This review summarizes published data on sofosbuvir-based regimens for patients infected with HCV GT1 with a focus on evaluating the optimal and possible durations of treatment. METHODS: PubMed and conference abstract books published between 2011-2015 were searched. RESULTS: HCV treatment has decreased from 24 week regimens to studies done as short as 4 weeks. History of prior treatment or cirrhosis have consistently shown lower SVR12 rates with shorter duration therapies. Low cure rates have been seen in patients within 4 week trials, however, select patients with low fibrosis scores, low HCV VL and HCV GT-1b have moderate cure rates. CONCLUSION: Most patients will require 12-24 weeks of therapy. Further studies are needed to elucidate the predictors of treatment response to short duration therapies and optimal combination of DAAs.
UNLABELLED: This review summarizes published data on sofosbuvir-based regimens for patients infected with HCV GT1 with a focus on evaluating the optimal and possible durations of treatment. METHODS: PubMed and conference abstract books published between 2011-2015 were searched. RESULTS: HCV treatment has decreased from 24 week regimens to studies done as short as 4 weeks. History of prior treatment or cirrhosis have consistently shown lower SVR12 rates with shorter duration therapies. Low cure rates have been seen in patients within 4 week trials, however, select patients with low fibrosis scores, low HCV VL and HCV GT-1b have moderate cure rates. CONCLUSION: Most patients will require 12-24 weeks of therapy. Further studies are needed to elucidate the predictors of treatment response to short duration therapies and optimal combination of DAAs.
Authors: Samah A Loutfy; Mostafa H Elberry; Khaled Yehia Farroh; Hossam Taha Mohamed; Aya A Mohamed; ElChaimaa B Mohamed; Ahmed Hassan Ibrahim Faraag; Shaker A Mousa Journal: Int J Nanomedicine Date: 2020-04-22